These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34730107)

  • 1. Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease.
    Jeong S; Oh YH; Choi S; Chang J; Kim SM; Son JS; Lee G; Kim W; Park SM
    Gut Liver; 2022 Jul; 16(4):589-598. PubMed ID: 34730107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham Heart Study.
    Mellinger JL; Pencina KM; Massaro JM; Hoffmann U; Seshadri S; Fox CS; O'Donnell CJ; Speliotes EK
    J Hepatol; 2015 Aug; 63(2):470-6. PubMed ID: 25776891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.
    Chung GE; Yu SJ; Yoo JJ; Cho Y; Lee KN; Shin DW; Kim YJ; Yoon JH; Han K; Cho EJ
    Cancer Commun (Lond); 2023 Aug; 43(8):863-876. PubMed ID: 37337385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort study.
    Ahmed HS; Wang N; Carr JJ; Ding J; Terry JG; VanWagner LB; Hou L; Huo Y; Palmisano J; Zheng Y; Benjamin EJ; Long MT
    Hepatology; 2023 Jun; 77(6):2063-2072. PubMed ID: 36651168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study.
    Park J; Kim G; Kim BS; Han KD; Kwon SY; Park SH; Lee YB; Jin SM; Kim JH
    Cardiovasc Diabetol; 2022 Apr; 21(1):53. PubMed ID: 35429980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study.
    Park J; Kim G; Kim H; Lee J; Jin SM; Kim JH
    Cardiovasc Diabetol; 2022 Dec; 21(1):287. PubMed ID: 36564787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
    Simon TG; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
    Gut; 2022 Sep; 71(9):1867-1875. PubMed ID: 34489307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.
    Younossi ZM; Stepanova M; Ong J; Yilmaz Y; Duseja A; Eguchi Y; El Kassas M; Castellanos-Fernandez M; George J; Jacobson IM; Bugianesi E; Wong VW; Arrese M; de Ledinghen V; Romero-Gomez M; Mendez-Sanchez N; Ahmed A; Wong R; Papatheodoridis G; Serfaty L; Younossi I; Nader F; Ziayee M; Afendy A;
    Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1625-1633.e1. PubMed ID: 30476585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal muscle mass and abdominal obesity are independent predictors of hepatic steatosis and interact to predict ten-year cardiovascular disease incidence: Data from the ATTICA cohort study.
    Kouvari M; Polyzos SA; Chrysohoou C; Skoumas J; Pitsavos CS; Panagiotakos DB; Mantzoros CS
    Clin Nutr; 2022 Jun; 41(6):1281-1289. PubMed ID: 35504171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population.
    Ciardullo S; Cannistraci R; Mazzetti S; Mortara A; Perseghin G
    Front Endocrinol (Lausanne); 2021; 12():711484. PubMed ID: 34381424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive tools for liver steatosis and steatohepatitis predict incidence of diabetes, cardiovascular disease and mortality 20 years later: The ATTICA cohort study (2002-2022).
    Kouvari M; Chrysohoou C; Damigou E; Barkas F; Kravvariti E; Liberopoulos E; Tsioufis C; Sfikakis PP; Pitsavos C; Panagiotakos D; Mantzoros CS;
    Clin Nutr; 2024 Mar; 43(3):900-908. PubMed ID: 38387279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease is an early predictor of metabolic diseases in a metabolically healthy population.
    Yang S; Kwak S; Lee JH; Kang S; Lee SP
    PLoS One; 2019; 14(11):e0224626. PubMed ID: 31682638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease.
    Arvind A; Henson JB; Osganian SA; Nath C; Steinhagen LM; Memel ZN; Donovan A; Balogun O; Chung RT; Simon TG; Corey KE
    Hepatol Commun; 2022 Feb; 6(2):309-319. PubMed ID: 34558862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease.
    Simon TG; Roelstraete B; Alkhouri N; Hagström H; Sundström J; Ludvigsson JF
    Gut; 2023 Mar; 72(3):573-580. PubMed ID: 36522149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of fatty liver index with the risk of incident cardiovascular disease and acute myocardial infarction.
    Olubamwo OO; Virtanen JK; Voutilainen A; Kauhanen J; Pihlajamäki J; Tuomainen TP
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1047-1054. PubMed ID: 29912803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic steatosis is associated with cardiometabolic risk in a rural Indian population: A prospective cohort study.
    Barik A; Shah RV; Spahillari A; Murthy VL; Ambale-Venkatesh B; Rai RK; Das K; Santra A; Hembram JR; Bhattacharya D; Freedman JE; Lima J; Das R; Bhattacharyya P; Das S; Chowdhury A
    Int J Cardiol; 2016 Dec; 225():161-166. PubMed ID: 27723535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
    Moon JH; Jeong S; Jang H; Koo BK; Kim W
    EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.